名稱 | EML4-ALK V3b/BaF3 |
型號(hào) | CBP73186 |
報(bào)價(jià) | ![]() |
特點(diǎn) | EML4-ALK V3b/BaF3,母細(xì)胞:BaF3,凍存條件:90% FBS+10% DMSO |
產(chǎn)品搜索
相關(guān)文章
- 重磅!科學(xué)家成功利用免疫細(xì)胞運(yùn)輸抗癌藥物至腫瘤靶點(diǎn)
- 【連載-企業(yè)參考品】 前列腺癌的診斷參考品的選擇
- 3年回顧,賀教授敲錯(cuò)了基因?CXCR4 or CCR5
- 【產(chǎn)品推介】T細(xì)胞活化篩選模型
- 能量平衡的重要靶點(diǎn)——CRF1R和CRF2R
- 神舟十一號(hào)成功發(fā)射!哪些生物實(shí)驗(yàn)跟著上天了?
- 【新品上線】一種安全高效的中和抗體體外篩選模型
- 基于納米顆粒的組合免疫療法對(duì)致命性癌癥發(fā)起三重打擊
- JAK2激酶抑制劑細(xì)胞篩選模型
- 【產(chǎn)品推介】VEGFR-2(KDR)小分子抑制劑細(xì)胞篩選模型
聯(lián)系我們
電話:4008750250
號(hào)碼:
手機(jī):18066071954
地址:南京市棲霞區(qū)緯地路9號(hào)
Email: zhangxiangwen@cobioer.com
產(chǎn)品展示 / PRODUCTS
藥靶細(xì)胞株 > kinase激酶細(xì)胞株 > CBP73186EML4-ALK V3b/BaF3

- 詳細(xì)內(nèi)容
CBP73186 | |
I. Introduction | |
Cell Line Name: | EML4-ALK V3b/BaF3 |
Host Cell: | Ba/F3 |
Stability: | 16 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.) |
Application: | Anti-proliferation assay and PD assay |
Freeze Medium: | 90% FBS+10% DMSO |
Complete Culture Medium: | RPMI-1640+10% FBS+2ug/ml puromycin |
Mycoplasma Status: | Negative |
II.Background | |
Approximately 3–7% of lung tumors harbor ALK fusions (Koivunen et al. 2008; Kwak et al. 2010; Shinmura et al. 2008; Soda et al. 2007; Takeuchi et al. 2008; Wong et al. 2009). ALK fusions are more commonly found in light smokers (< 10 pack years) and/or never-smokers (Inamura et al. 2009; Koivunen et al. 2008; Kwak et al. 2010; Soda et al. 2007; Wong et al. 2009). ALK fusions are also associated with younger age (Inamura et al. 2009; Kwak et al. 2010; Wong et al. 2009) and adenocarcinomas with acinar histology (Inamura et al. 2009; Wong et al. 2009) or signet-ring cells (Kwak et al. 2010). Clinically, the presence of EML4-ALK fusions is associated with EGFR tyrosine kinase inhibitor (TKI) resistance (Shaw et al. 2009). Multiple different ALK rearrangements have been described in NSCLC. The majority of these ALK fusion variants are comprised of portions of the echinoderm microtubule-associated protein-like 4 (EML4) gene with the ALK gene. At least nine different EML4-ALK fusion variants have been identified in NSCLC (Figure 1; Choi et al. 2008; Horn and Pao 2009; Koivunen et al. 2008; Soda et al. 2007; Takeuchi et al. 2008; Takeuchi et al. 2009; Wong et al. 2009). In addition, non-EML4 fusion partners have also been identified, including KIF5B-ALK (Takeuchi et al. 2009) and TFG-ALK (Rikova et al. 2007). Clinically, the presence of an ALK rearrangement is detected by fluorescence in situ hybridization (FISH) with an ALK break apart probe. FISH testing is not able to discern which particular ALK fusion is found in a clinical sample. | |
III. Representative Data | |
1. WB of EML4-ALK V3b/BaF3 expression | |
![]() | |
Figure 1. WB of ALK expression | |
2. Anti-proliferation assay | |
Figure 2. Anti-proliferation assay of three reference compounds on the EML4-ALK V3b/BaF3 Stable Cell Line |